In the past two decades, five EGFR tyrosine kinase inhibitors (TKIs) have become commercially available for the management of advanced NSCLC with common EGFR-sensitizing mutations [i.e., EGFR exon 19 deletions or exon 21 mutations (L858R)]: erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib (Table 1; Figure 1) [3,4,5,6,7,8,9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.